Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tetraphase raising $150m

This article was originally published in Scrip

Executive Summary

Massachusetts-based antibiotic drug developer Tetraphase Pharmaceuticals is aiming to raise $150m through a public offering of 4,300,000 shares of common stock at $35 per share. The offer is expected to close on or around 17 March 2015. Tetraphase reported positive Phase III data in December last year for its lead antibiotic compound eravacycline as a treatment for complicated intra-abdominal infections. Data from a second Phase III trial in complicated urinary tract infections are expected by mid-2015. Tetraphase is aiming to file a New Drug Application to the FDA for eravacycline by the end of this year. BMO Capital Markets, Stifel and Guggenheim Securities are acting as joint bookrunning managers for the offering and Nomura and SunTrust Robinson Humphrey are acting as co-managers.

You may also be interested in...

Femtech Presents Enticing Market Opportunity

A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.

Execs On The Move, Sep 2020

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Snapshot: September Highlights

A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts